Article
No evidence of FGFR3 mutations in prostate cancer.
The Prostate - 1 May 2011
Zuiverloon Tahlita C M, Boormans Joost L, Trapman Jan, van Leenders Geert J L H, Zwarthoff Ellen C
Abstract excerpt
BACKGROUND: FGFR3 mutations are associated with a good clinical disease course in bladder tumors. Currently, prognostic markers to stratify prostate cancer (PCa) patients for conservative management are lacking. Conflicting results have been found on the presence of FGFR3 mutations in PCa. Our objective was to determine the prevalence of FGFR3 mutations in a subset of prostate tumors. Next, determine the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
